Progestins and bone;Gestagene und Knochenstoffwechsel

Zentralblatt fur Gynakologie

Volumn 119, Issue SUPPL. 2, 1997, Pages 70-74

  Thijssen, J H H ^a  

^a Academisch Ziekenhuis G02625   (Netherlands)

Author keywords

Bone; Hormone replacement therapy; Oestrogen; Progestin

Indexed keywords

ANDROGEN; DANAZOL; DESOGESTREL; DROLOXIFENE; ESTROGEN; GESTAGEN; GESTRINONE; MEDROXYPROGESTERONE ACETATE; METHYLTESTOSTERONE; NORETHISTERONE ACETATE; NORGESTIMATE; NORGESTREL; PROGESTERONE; RALOXIFENE; TAMOXIFEN; TESTOSTERONE; TIBOLONE;

BONE DENSITY; BONE MASS; BONE METABOLISM; BONE MINERAL; CLINICAL TRIAL; DOSE RESPONSE; FEMALE; HORMONE SUBSTITUTION; HUMAN; NONHUMAN; OSTEOPOROSIS; REVIEW;

BONE DENSITY; CLIMACTERIC; DRUG THERAPY, COMBINATION; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; PROGESTERONE CONGENERS;

EID: 0030731644     PISSN: 00444197     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. Adachi JD, Sargeant EJ, Sagle MA, Lament D, Fawcett PD, Bensen WG, McQueen M, Nazir DJ, Goldsmith CH: A double-blind randomised controlled trial of the effects of medroxyprogesterone acetate on bone density of women taking oestrogen replacement therapy. Brit J Obstet Gynaecol 104 (1997) 64-70
2. Albright F, Smith PH, Richardson AM: Postmenopausal osteoporosis - its clinical features. JAMA 116 (1941) 2465-2473
3. Andrews WC: Continuous combined estrogen/progestin hormone replacement therapy. Clin Ther 17 (1995) 812-826
4. Berning B, Kuijk CV, Kuiper JW, Bennink HJ, Kicovic P, Fauser BC: Effects of two doses of tibolone on trabecular and cortical bone lossses in early postmenopausal women: a two year randomized, placebo-controlled study. Bone 19 (1996) 395-399
5. Bulun SE: Aromatase deficiency in women and men: would you have predicted the phenotypes? J Clin Endocrinol Metab 81 (1996) 867-871
6. Casper RF, MacLusky NJ, Vanin C, Brown TJ: Rationale for estrogen with interrupted progestin as a new low-dose hormonal replacement therapy. J Soc Gynecol Investig 3 (1996) 225-234
7. Christiansen C, Riis BJ: 17β-estradiol and continuous norethisterone: a unique treatment for established osteoporosis in elderly women. J Clin Endocrinol Metab 74 (1990) 836-840
8. Cromer BA, Blair JM, Mahan JD, Zibners L, Naumovski Z: A retrospective comparison of bone density in adolescent girls receiving depot medroxyprogesterone acetate (Depo-Provera), levonorgestrel (Norplant), or oral contraceptives. J Pediatr 129 (1996) 671-676
9. Davis SR, McCloud P, Strauss BJ, Burger H: Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality. Maturitas 21 (1995) 227-236
10. Dawood MY: Hormonal therapies for endometriosis: implications for bone metabolism. Acta Obstet Gynecol Scand 159 (1994) Suppl, 22-34
11. Dawood MY, Obasiolu CW, Ramos J, Khan-Dawood FS: Clinical, endocrine, and metabolic effects of two doses of gestrinone in treatment of pelvic endometriosis. Am J Obster Gynecol 176 (1997) 387-394
12. DeCherney A: Bone-sparing properties of oral contraceptives. Am J Obstet Gynecol 174 (1996) 15-20
13. Dören M, Reuther G, Minne HW, Schneider HP: Superior compliance and efficacy of continuous combined oral estrogen-progestogen replacement therapy in postmenopausal women. Am J Obstet Gynecol 173 (1995) 1446-1451
14. Draper MW, Flowers DE, Huster WJ, Neild JA, Harper KD, Arnaud C: A controlled trial of raloxifene (LY139481) HCL: impact on bone turnover and serum lipid profile in healthy postmenopausal women. J Bone Miner Res 11 (1996) 835-842
15. Evans SF, Dawie MW: Low and conventional dose transdermal oestradiol are equally effective at preventing bone loss in spine and femur at all postmenopausal ages. Clin Endocrinol 44 (1996) 79-84
16. Fukushima M: Changes in bone mineral content following hormone treatment for endometriosis. Int J Gynaecol Obstet 50 Suppl 1 (1995) S17-22
17. Grey AB, Cundy TF, Reid IR: Continuous combined oestrogen/progestin therapy is well tolerated and increases bone density at the hip and spine in postmenopausal osteoporosis. Clin Endocrinol 40 (1994) 671-677
18. Grey A, Cundy T, Evans M, Reid I: Medroxyprogesterone acetate enhances the spinal bone mineral density response to oestrogen in late postmenopausal women. Clin Endocrinol 44 (1996) 293-296
19. Hillard TC, Whitcroft SJ, Marsh MS, Ellerington MC, Lees M, Whitehead MI, Stevenson SJ: Long-term effects of transdermal and oral hormone replacement therapy on postmenopausal bone loss. Osteoporos Int 4 (1994) 341-348
20. Howell R, Edmonds DK, Dowsett M, Crook D, Lees B, Stevenson JC: Gonadotropin-releasing hormone analogue (go-serelin) plus hormone replacement therapy for the treatment of endometriosis: a randomized controlled trial. Fertil Steril 64 (1995) 474-481
21. Josse RG: Prevention and management of osteoporosis: consensus statement from the Scientific Board of the Osteoporosis Society of Canada. 3. Effects of ovarian hormone therapy on skeletal and extraskeletal tissues in women. Can Med Assoc J 155 (1996) 929-934
22. Kanis JA: The menopause and the skeleton: key issues. Ballieres Clin Obstet Gynecol 10 (1996) 469-481
23. Kanis JA: Medroxyprogesterone and bone mineral density response to oestrogen. Clin Endocrinol 44 (1996) 297-298
24. Kasra M, Vanin CM, MacLusky NJ, Casper RF, Grynpas MD: Effects of different estrogen and progestin regimens on the mechanical properties of rat femur. J Orthop Res 15 (1997) 118-123
25. Kaunitz AM: Long-acting injectable contraception with depot medroxyprogesterone acetate. Am J Obstet Gynecol 170 (1994) 1543-1549
26. Ke HZ, Chen HK, Simmons HA, Qi H, Crawford DT, Pirie CM, Chidsey-Frink KL, Ma YF, Jee WS, Thompson DD: Comparative effects of droloxifene, tamoxifen, and estrogen on bone, serum cholesterol, and uterine histology in the ovariectomized rat model. Bone 20 (1997) 31-39
27. Korach KS, Couse JF, Curtis SW, Washburn TF, Lindzey J, Kimbro KS, Eddy EM, Migliaccio S, Snedeker SM, Lubahn DB, Schomberg DW, Smith EP: Estrogen receptor gene disruption: molecular characterisation and experimental and clinical phenotypes. Recent Prog Horm Res 51 (1996) 159-186
28. Lau KH, Wang SP, Linkhart TA, Demarest KT, Baylink DJ: Picomolar norethindrone in vitro stimulates the cell proliferation and activity of a human osteosarcoma cell line and increases bone collagen synthesis without an effect on bone resorption. J Bone Miner Res 9 (1994) 695-704
29. Lindsay PC, Shaw RW, Bennink HJ, Kicovic P: The effect of add-back treatment with tibolone (Livial) on patients treated with the gonadotropin-releasing hormone agonist triptorelin (Decapeptyl). Fertil Steril 65 (1996) 342-348
30. Lindsay R: The oestrogen receptor in bone-evolution of our knowledge. Brit J Obstet Gynaecol 103 13 (1996) Suppl, 16-19
31. Lindsay R: The menopause and osteoporosis. Obstet Gynecol 87 (1996) Suppl, 16S-19S
32. MacLennan AH, MacLennan A, Wenzel S, Chambers HM, Eckert K: Continuous low-dose oestrogen and progestogen hormone replacement therapy: a randomized trial Med J Austr 159 (1993) 102-106
33. Makarainen L, Ronnberg L, Kauppila A: Medroxyprogesterone acetate supplementation diminishes the hypooestrogenic side effects of gonadotropin-releasing hormone agonist without changing its efficacy in endometriosis. Fertil Steril 65 (1996) 29-34
34. Marchesoni D, Dal-Pozzo M, Dal-Magro L, Paternoster DM, Ferroni E, Maggino T, Romagnolo C, Mozzanega B: Transdermal estroprogestin versus transdermal estrogen plus oral dihydrogesterone replacement in menopause. J Endocrinol Invest 19 (1996) 268-272
35. Marks S: Premenopausal bone loss and depot medroxyprogesterone acetate administration. Int J Gynaecol Obstet 47 (1994) 269-272
36. Morishima A, Grumbach MM, Simpson ER, Fischer C, Kenan Q: Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab 80 (1995) 3689-3698
37. Munnoz-Torres M, Jodar E, Quesada M, Escobar-Jimenez F: Bone mass in androgen-insensitivity syndrome: response to hormonal replacement therapy. Calcif Tissue Int 57 (1995) 94-96
38. Naessen T, Olsson SE, Gudmonson J: Differential effects on bone density of progestogen-only methods for contraception in premenopausal women. Contraception 52 (1995) 35-39
39. Notelovitz M; Estrogen therapy and osteoporosis : principles and practice. Am J Med Sci 313 (1997) 2-12
40. PEPI Writing Group: Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA 276 (1996) 1389-1396
41. Perrone G, Falaschi P, Capri O, Pastore R, Galoppi P, D'Urso R, Martochia A, Anelli G, Zichella L: Hormonal and metabolic effects of transdermal estradiol/progestagen administration in postmenopausal women. Int J Fertil Menopausal Stud 39 (1994) 202-207
42. Prelevic GM, Beljic T, Balint-Peric L, Petrvic J, Elliesen J: Effect of two different progestins (cyproterone acetate and norgestrel), administered in a cyclical estradiol valerate regimen, on markers of bone turnover. Gynecol Endocrinol 8 (1994) 209-214
43. Prelevic GM, Bartram C, Wood J, Okolo S, Ginsburg J: Comparative effects on bone mineral density of tibolone, transdermal estrogen and oral estrogen/progestogen therapy in postmenopausal women. Gynecol Endocrinol 10 (1996) 413-420
44. Prior JC: Progesterone as a bone-trophic hormone. Endocr Rev 11 (1990) 386-398
45. Prior JC, Vigna YM, Barr SI, Rexworthy C, Lentle BC: Cyclic medroxyprogesterone treatment increases bone density: a controlled trial in active women with menstrual cycle disturbances. Am J Med 96 (1994) 521-530
46. Prior JC: High dose medroxyprogesterone, rates of bone resorption and changes in spinal bone density. J Clin Endocrinol Metab 81 (1996) 4500-4501
47. Raisz LG, Wiita B, Arts A, Bowen A, Schwartz S, Trahiotis M, Shoukri K, Smith J: Comparison of the effects of estrogen alone and estrogen plus androgen on biochemical markers of bone formation and resorption in postmenopausal women. J Clin Endocrinol Metab 81 (1996) 37-43
48. Rizzoli R, Bonjour JP: Hormones and bone. Lancet 349 Suppl (1997) S120-S123
49. Rosenquist C, Bonde M, Fledelius C, Qvist P: A simple enzyme-linked immunosorbent assay of human osteocalcin. Clin Chem 40 (1994) 1258-1264
50. Sato M, Rippy MK, Bryant HU: Raloxifene, tamoxifene, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats. FASEB J 10 (1996) 905-912
51. Smith EP, Boyd J, Frank GR: Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med 331 (1994) 1056-1061
52. Speroff L, Rowan J, Symons J, Genant H, Wilborn W: The comparative effect on bone density, endometrium, and li- pids of continuous hormones as replacement therapy (CHART study). JAMA 276 (1996) 1397-1403
53. Udoff L, Langenberg P, Adashi EY: Combined continuous hormone replacement therapy: a critical review. Obstet Gynecol 86 (1995) 306-316
54. Vaananen HK, Harkonen PL: Estrogen and bone metabolism. Maturitas 23 (1996) Suppl, S65-69
55. Vanin CM, MacLusky NJ, Chachra D, Kasra M, Grynpas MD, Casper RF: Lumbar vertebral density and mechanical properties in aged ovariectomized rats treated with estrogen and norethindrone or norgestimate. Am J Obstet Gynecol 173 (1995) 1491-1498
56. Verhaar HJ, Damen CA, Duursma SA, Scheven BA: A comparison of the action of progestins and estrogen on the growth and differentiation of normal adult human osteo-blast-like cells in vitro. Bone 15 (1994) 307-311
57. Verhaar HJ, Damen CA, Duursma SA, Scheven BA: Comparison of the action of 17β-estradiol and progestins with insuline-like growth factors-I/-II and TGF-β-1 on the growth of normal adult human bone forming cells. Maturitas 21 (1995) 237-243
58. Virutamasen P, Wangsuphachart S, Reinprayoon D, Kriengsinyot R, Leepipatpaiboon S, Gua S: Trabecular bone in long-term depot-medroxyprogesterone acetate users. Asia Oceania J Obstet Gynaecol 20 (1994) 269-274
59. Webber CE, Blake JM, Chambers LF, Roberts JG: Effect of two years of hormone replacement upon bone mass, serum lipids and lipoproteins. Maturitas 19 (1994) 13-23
60. Westhoff C: Depot medroxyprogesterone acetate contraception. Metabolic parameters and mood changes. J Reproduct Med 41 (1996) Suppl, 401-406